Châtillon, France, April 30, 2026DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today announced that VITESSE, its pivotal Phase 3 study ...
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF ...
On Wednesday, DBV Technologies SA (NASDAQ:DBVT) reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years. The FDA has outlined a clear Accelerated ...
DBV Technologies’ Viaskin Peanut Phase 3 VITESSE boosts blockbuster outlook; learn peak sales/valuation upside, key risks, ...
DBV plans to announce new data for its Viaskin Peanut peanut allergy drug at a conference later this week. The company awaits FDA feedback for the design of another study of Viaskin Peanut. DBV is ...
Shares of DBV TechnologiesDBVT launched to a three-year high Wednesday after the company reported promising results for its peanut allergy treatment in children ages 4 to 7. The biotech company is ...
Shares of DBV Technologies (NASDAQ: DBVT), a clinical-stage biopharmaceutical company, took a sharp turn for the worse today. Investors reacting to disappointing news about the development of Viaskin ...
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American ...
Zacks Investment Research on MSN
DBV Technologies (DBVT) upgraded to buy: What does it mean for the stock?
DBV Technologies S.A. (DBVT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
Shares in DBV Technologies have shot up after it presented positive clinical trial results with an immunotherapy for peanut allergy that was rejected by the FDA several years ago. The Paris, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results